Venous and Arterial Thromboembolism: See Boxed WARNINGS: Venous thromboembolic events (DVT and PE) and arterial thromboses (Ml and CVA) are increased in patients treated with REVLIMID. Existing patients can call 1-888-663-3488. Cellular Immunotherapy – T cells are the immune system’s "defender cells," which are responsible for finding and eliminating abnormal cells throughout the body. The patients at risk of TLS are those with high tumor burden prior to treatment.

The most common adverse reactions reported in ≥20% (Arm Rd Continuous): diarrhea (46%), anemia (44%), neutropenia (35%), fatigue (33%), back pain (32%), asthenia (28%), insomnia (28%), rash (26%), decreased appetite (23%), cough (23%), dyspnea (22%), pyrexia (21%), abdominal pain (21%), muscle spasms (20%), and thrombocytopenia (20%). Results from two early-phase clinical trials suggest that a form of immunotherapy that uses genetically engineered immune cells may be highly effective in patients with advanced multiple myeloma.. Prescribers and pharmacies must be certified with the.

"Cancer research not only saved my life but will potentially save members of my family.". Immunotherapy for multiple myeloma is a promising new treatment option, with the potential to result in long-term cancer remission similar to the results of allogeneic bone marrow transplantation with less risk for complications. Please see full Prescribing Information, including Boxed WARNINGS. REVLIMID is only available through a restricted distribution program, REVLIMID REMS®. Patients with known risk factors, including prior thrombosis, may be at greater risk and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Cell-based immunotherapy targets under evaluation in multiple myeloma clinical trials include: Immunomodulators manipulate the “brakes” and “gas pedals” of the immune system. Early Mortality in Patients With MCL: In another MCL study, there was an increase in early deaths (within 20 weeks); 12.9% in the REVLIMID arm versus 7.1% in the control arm. Let's spread the word about Immunotherapy! Click to share this page with your community. Multiple myeloma is diagnosed when elevated abnormal plasma cells in the bone marrow are detected, and a treatment regimen is structured around the symptoms of organ damage from the cancer. For people with multiple myeloma, abnormal plasma cells grow uncontrollably and crowd out healthy cells, including other types of white blood cells, platelets and red blood cells, which can lead to bone and calcium issues, low blood counts, kidney problems and infections. Copyright © 2020 Cancer Research Institute | Privacy Policy | Accessibility Statement. Antibody-drug conjugates (ADCs) are equipped with anti-cancer drugs that they can deliver to tumors. REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with MM who were treated with REVLIMID and dexamethasone therapy. erythropoietin-stimulating agents (ESAs) and estrogens may further increase the risk of thrombosis and their use should be based on a benefit-risk decision. Increased Mortality With Pembrolizumab: In clinical trials in patients with MM, the addition of pembrolizumab to a thalidomide analogue plus dexamethasone resulted in increased mortality. Multiple myeloma is a type of cancer that develops in plasma cells within the bone marrow. There are a number of immunotherapies, each working in a slightly different way. Impaired Stem Cell Mobilization: A decrease in the number of CD34+ cells collected after treatment (>4 cycles) with REVLIMID has been reported. Take into account both the potential benefit of REVLIMID and risk of SPM when considering treatment. Stop REVLIMID upon elevation of liver enzymes. Information about the REVLIMID REMS program is available at www.celgeneriskmanagement.com or by calling the manufacturer’s toll-free number 1-888-423-5436. The most frequently reported adverse reactions in ≥20% (REVLIMID arm) across both maintenance studies (Study 1, Study 2) were neutropenia (79%, 61%), thrombocytopenia (72%, 24%), leukopenia (23%, 32%), anemia (21%, 9%), upper respiratory tract infection (27%, 11%), bronchitis (4%, 47%), nasopharyngitis (2%, 35%), cough (10%, 27%), gastroenteritis (0%, 23%), diarrhea (54%, 39%), rash (32%, 8%), fatigue (23%, 11%), asthenia (0%, 30%), muscle spasm (0%, 33%), and pyrexia (8%, 20%). Moffit now offers Virtual Visits for patients. REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form. Need more information? If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. Avoid concomitant use of POMALYST with strong inhibitors of CYP1A2. Natural killer cells (NKs) and tumor infiltrating lymphocytes (TILs) can also be enhanced and reinfused in patients.

T-cell therapies, such as chimeric antigen receptor therapy (CAR-T), remove a patient’s T cells from his or her body, modify the T cells to recognize multiple myeloma cells as dangerous intruders, then reintroduce the T cells into the patient’s body to help fight the cancer. Patients with a prior history of Grade 4 rash associated with thalidomide treatment should not receive REVLIMID. In addition to the FDA-approved therapies listed above, there are several new classes of myeloma immunotherapy in clinical trials. ... immunotherapy appears largely ineffective.

This site is intended for US audiences only. POMALYST is only available through a restricted distribution program, POMALYST REMS®. NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488. Djordje Atanackovic, M.D. Myeloma cells grow in an out-of-control manner and accumulate in bone marrow. WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM. Pre-existing viral liver disease, elevated baseline liver enzymes, and concomitant medications may be risk factors. Periodically monitor digoxin plasma levels due to increased Cmax and AUC with concomitant REVLIMID therapy. Adverse reactions (≥15% in the POMALYST + low-dose dex arm and ≥2% higher than control) included neutropenia (51.3%), fatigue and asthenia (46.7%), upper respiratory tract infection (31%), thrombocytopenia (29.7%), pyrexia (26.7%), dyspnea (25.3%), diarrhea (22%), constipation (21.7%), back pain (19.7%), cough (20%), pneumonia (19.3%), bone pain (18%), edema peripheral (17.3%), peripheral neuropathy (17.3%), muscle spasms (15.3%), and nausea (15%). Plasma cells produce antibodies and play an important role in the body’s immune system function. Team CRI runs the 2020 TCS New York City Marathon and helps raise critic... Immunotherapy Patient Summit Goes Virtual. Consider alternative treatments. Monitoring and evaluation for TFR is recommended in patients with MCL, FL, or MZL. Monitor liver enzymes periodically.

With your help, we can fund more research and revolutionize the way cancer is treated—saving more lives. It is not known whether there is an interaction between dexamethasone and warfarin. Permanently discontinue REVLIMID for these reactions. Close monitoring of PT and INR is recommended in patients with MM taking concomitant warfarin.

REVLIMID®, REVLIMID REMS®, POMALYST®, and POMALYST REMS® are registered trademarks of Celgene Corporation. Discover the different proteins, pathways, and platforms that scientists and physicians are pursuing to develop new cancer treatments. Today, a range of immunotherapies—treatments that marshal the immune system to attack cancer—is available to patients with myeloma. Hepatotoxicity: Hepatic failure, including fatal cases, has occurred in patients treated with REVLIMID + dexamethasone. REVLIMID ® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM).. REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). Patients on therapy for del 5q MDS should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Advances against multiple myeloma have come at an especially rapid pace, with 10 new therapies approved in just the last 10 years. REVLIMID is not indicated and not recommended for use in CLL outside of controlled clinical trials.

To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program, the REVLIMID REMS® program. © 2019 Celgene Corporation       10/19       US-POM-19-0263. This can attract the attention of immune cells to eliminate the main tumor and potentially other tumors throughout the body. Patients may require a dose interruption and/or dose reduction. A secure website for patients to access their medical care at Moffitt. Through our ongoing grant and fellowship programs, clinical studies, and multiple myeloma initiatives, we provide funding for research that seeks to further understand and more effectively treat multiple myeloma.

Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday, STORIES TO INSPIRE YOU ON YOUR JOURNEY THROUGH CANCER, Immunomodulatory agents (IMIDs): These agents exert their biologic effect against myeloma partly by stimulating the patient’s own immune cells.

For Moffitt faculty & staff members to access MoffittNet applications.